Compare Stocks: CGTX, BIOA, EYPT, and VNDA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIOA BioAge Labs	$5.10 -7.8%	$7.85	$4.81 ▼ $25.95	$234.07M	1.08	869,897 shs	464,221 shs
CGTX Cognition Therapeutics	$0.72 +2.6%	$0.94	$0.55 ▼ $1.83	$68.35M	1.8	627,875 shs	571,534 shs
EYPT Eyepoint Pharmaceuticals	$0.40 -5.5%	$3.70	$0.39 ▼ $19.11	$34.87M	1.67	16.16 million shs	13.30 million shs
VNDA Vanda Pharmaceuticals	$4.01 -1.0%	$4.94	$3.88 ▼ $9.94	$242.46M	0.69	1.13 million shs	830,812 shs

The 7 Best High-Yield Dividend Stocks for 2027

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIOA BioAge Labs	0.00%	+5.37%	-29.26%	-76.57%	-15.70%
CGTX Cognition Therapeutics	0.00%	-1.51%	-24.40%	-21.83%	-57.72%
EYPT Eyepoint Pharmaceuticals	0.00%	-86.47%	-88.92%	-96.68%	-96.47%
VNDA Vanda Pharmaceuticals	0.00%	-0.50%	-19.48%	-22.59%	-24.91%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIOA BioAge Labs	$5.10 -7.8%	$7.85	$4.81 ▼ $25.95	$234.07M	1.08	869,897 shs	464,221 shs
CGTX Cognition Therapeutics	$0.72 +2.6%	$0.94	$0.55 ▼ $1.83	$68.35M	1.8	627,875 shs	571,534 shs
EYPT Eyepoint Pharmaceuticals	$0.40 -5.5%	$3.70	$0.39 ▼ $19.11	$34.87M	1.67	16.16 million shs	13.30 million shs
VNDA Vanda Pharmaceuticals	$4.01 -1.0%	$4.94	$3.88 ▼ $9.94	$242.46M	0.69	1.13 million shs	830,812 shs

The 7 Best High-Yield Dividend Stocks for 2027

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIOA BioAge Labs	0.00%	+5.37%	-29.26%	-76.57%	-15.70%
CGTX Cognition Therapeutics	0.00%	-1.51%	-24.40%	-21.83%	-57.72%
EYPT Eyepoint Pharmaceuticals	0.00%	-86.47%	-88.92%	-96.68%	-96.47%
VNDA Vanda Pharmaceuticals	0.00%	-0.50%	-19.48%	-22.59%	-24.91%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BIOA BioAge Labs	2.63	Moderate Buy	$33.00	547.06% Upside
CGTX Cognition Therapeutics	2.50	Moderate Buy	$3.33	363.74% Upside
EYPT Eyepoint Pharmaceuticals	2.00	Hold	$21.85	5,301.73% Upside
VNDA Vanda Pharmaceuticals	2.44	Hold	$13.08	226.27% Upside

Current Analyst Ratings Breakdown

Latest CGTX, BIOA, EYPT, and VNDA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/20/2026	EYPT Eyepoint Pharmaceuticals	Laidlaw Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy ➝ Hold
10/20/2026	EYPT Eyepoint Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Sector Perform	$1.00
10/20/2026	EYPT Eyepoint Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Neutral
10/20/2026	EYPT Eyepoint Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Neutral ➝ Underweight
10/20/2026	EYPT Eyepoint Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform ➝ Neutral	$0.50
10/19/2026	EYPT Eyepoint Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Buy ➝ Neutral
10/19/2026	EYPT Eyepoint Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Buy ➝ Hold	$1.00
10/15/2026	VNDA Vanda Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/11/2026	BIOA BioAge Labs	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Neutral	$8.00
10/11/2026	BIOA BioAge Labs	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold
10/8/2026	BIOA BioAge Labs	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 10/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BIOA BioAge Labs	$8.99M	26.04	N/A	N/A	$7.59 per share	0.67
CGTX Cognition Therapeutics	N/A	N/A	N/A	N/A	$0.39 per share	N/A
EYPT Eyepoint Pharmaceuticals	$2.79M	12.51	N/A	N/A	$3.70 per share	0.11
VNDA Vanda Pharmaceuticals	$215.72M	1.12	N/A	N/A	$5.54 per share	0.72

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BIOA BioAge Labs	-$80.61M	-$2.38	N/A	N/A	N/A	-912.26%	-28.99%	-27.09%	N/A
CGTX Cognition Therapeutics	-$23.49M	-$0.17	N/A	N/A	N/A	N/A	-50.17%	-40.22%	11/5/2026 (Estimated)
EYPT Eyepoint Pharmaceuticals	-$231.96M	-$3.74	N/A	N/A	N/A	-10,994.73%	-135.81%	-108.35%	11/4/2026 (Estimated)
VNDA Vanda Pharmaceuticals	-$220.47M	-$4.63	N/A	N/A	N/A	-127.41%	-49.81%	-33.29%	10/28/2026 (Estimated)

Latest CGTX, BIOA, EYPT, and VNDA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	CGTX Cognition Therapeutics	-$0.07	N/A	N/A	N/A	$5.30 million	N/A
11/4/2026	Q3 2026	EYPT Eyepoint Pharmaceuticals	-$0.9304	N/A	N/A	N/A	$0.23 million	N/A
10/28/2026	Q3 2026	VNDA Vanda Pharmaceuticals	-$0.72	N/A	N/A	N/A	$69.20 million	N/A
8/6/2026	Q2 2026	CGTX Cognition Therapeutics	-$0.0633	-$0.04	+$0.0233	-$0.04	$5.00 million	N/A
8/5/2026	Q2 2026	BIOA BioAge Labs	-$0.65	-$0.58	+$0.07	-$0.58	N/A	$2.45 million
8/5/2026	Q2 2026	EYPT Eyepoint Pharmaceuticals	-$1.01	-$1.09	-$0.08	-$0.2720	$0.45 million	$0.51 million
8/5/2026	Q2 2026	VNDA Vanda Pharmaceuticals	-$0.5825	-$1.04	-$0.4575	-$1.04	$61.93 million	$50.53 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BIOA BioAge Labs	N/A	N/A	N/A	N/A	N/A
CGTX Cognition Therapeutics	N/A	N/A	N/A	N/A	N/A
EYPT Eyepoint Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VNDA Vanda Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BIOA BioAge Labs	N/A	17.19	17.19
CGTX Cognition Therapeutics	N/A	7.03	7.03
EYPT Eyepoint Pharmaceuticals	N/A	4.50	4.46
VNDA Vanda Pharmaceuticals	0.01	1.61	1.60

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BIOA BioAge Labs	N/A
CGTX Cognition Therapeutics	43.35%
EYPT Eyepoint Pharmaceuticals	99.41%
VNDA Vanda Pharmaceuticals	88.14%

Insider Ownership

Company	Insider Ownership
BIOA BioAge Labs	17.55%
CGTX Cognition Therapeutics	11.11%
EYPT Eyepoint Pharmaceuticals	5.13%
VNDA Vanda Pharmaceuticals	10.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BIOA BioAge Labs	62	45.90 million	37.84 million	Optionable
CGTX Cognition Therapeutics	14	95.09 million	84.53 million	Not Optionable
EYPT Eyepoint Pharmaceuticals	214	86.21 million	81.79 million	Optionable
VNDA Vanda Pharmaceuticals	533	60.46 million	53.99 million	Optionable

CGTX, BIOA, EYPT, and VNDA Headlines

Recent News About These Companies

Vanda Pharmaceuticals (VNDA) Set to Post Earnings on Wednesday

October 23 at 2:10 AM | americanbankingnews.com

Vanda Pharmaceuticals (VNDA) Projected to Release Quarterly Earnings on Wednesday

October 23 at 2:10 AM | marketbeat.com

Vanda Pharmaceuticals to Announce Third Quarter 2026 Financial Results on October 28, 2026

October 21, 2026 | prnewswire.com

Vanda puts VQW-765 on hold: Vanda Pharmaceuticals stock costs EUR 3.64

October 21, 2026 | ad-hoc-news.deA

Vanda puts VQW-765 on hold: what it means for Vanda Pharmaceuticals stock

October 18, 2026 | ad-hoc-news.deA

Vanda Pharmaceuticals: Cash Is Running Out Faster Than The Launches

October 15, 2026 | seekingalpha.com

Vanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program

October 15, 2026 | finanznachrichten.de

Vanda Pharmaceuticals Says Experimental Anxiety Treatment Misses Primary Endpoint

October 15, 2026 | benzinga.com

Vanda Pharmaceuticals Says Experimental Anxiety Treatment Misses Primary Endpoint

October 15, 2026 | benzinga.com

Vanda Pharmaceuticals stock falls after anxiety drug trial fails

October 14, 2026 | finance.yahoo.com

Vanda Pharmaceuticals' Late-Stage Study of VQW-765 to Treat Acute Anxiety Fails to Meet Primary Endpoint

October 14, 2026 | finance.yahoo.com

Vanda says anxiety drug failed main goal of late-stage study, puts program on hold

October 14, 2026 | reuters.com

Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program

October 14, 2026 | prnewswire.com

Vanda’s Tasimelteon Study Completion: What Sleep Trial Progress Means for VNDA Investors

October 9, 2026 | tipranks.com

Vanda Pharmaceuticals (NASDAQ:VNDA) Stock Rating Lowered by Zacks Research

October 8, 2026 | marketbeat.com

Vanda Pharmaceuticals (NASDAQ:VNDA) Stock Rating Reaffirmed as Buy by HC Wainwright

October 5, 2026 | marketbeat.com

Vanda Pharmaceuticals: Buy Rating Reaffirmed as HETLIOZ Phase 3 Success in DSWPD Supports sNDA; $20 Price Target Maintained

October 5, 2026 | tipranks.com

Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting

October 2, 2026 | prnewswire.com

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Receives Consensus Rating of "Moderate Buy" from Analysts

October 2, 2026 | marketbeat.com

Vanda: 'Hold' On Hetlioz Trial Win, But Several Risk Factors Remain For It

October 1, 2026 | seekingalpha.com

VNDA Stock Fades After Hetlioz Sleep-Trial Win — Here’s Why

September 30, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGTX, BIOA, EYPT, and VNDA Company Descriptions

BioAge Labs NASDAQ:BIOA

$5.10 -0.43 (-7.78%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$5.17 +0.07 (+1.33%)

As of 10/23/2026 07:52 PM Eastern

We are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging. Our primary focus is metabolic disease, one of the greatest global healthcare challenges. Azelaprag, our lead product candidate, is an orally available small molecule that has been well-tolerated in 265 individuals across eight Phase 1 clinical trials. In preclinical obesity models, azelaprag demonstrated the ability to more than double the weight loss induced by a glucagon-like-peptide-1 receptor (GLP-1R) agonist while also restoring healthy body composition and improving muscle function. These preclinical results are supported by our Phase 1b clinical trial in older adults on bed rest where we observed decreased muscle atrophy, preservation of muscle quality and improved metabolism in subjects treated with azelaprag over a 10-day period. We plan to assess azelaprag’s potential to drive significant improvements in weight loss when combined with a GLP-1R agonist in two Phase 2 clinical trials. While the results of these preclinical studies and early clinical trials have demonstrated the potential use of azelaprag for the treatment of metabolic disease, they may not be predictive of the results of later-stage clinical trials. The ongoing STRIDES clinical trial will assess azelaprag in combination with tirzepatide, marketed as Zepbound® by Eli Lilly and Company (Lilly), with topline results anticipated in the third quarter of 2025. The second Phase 2 clinical trial will assess azelaprag in combination with semaglutide, marketed as Wegovy® by Novo Nordisk, with initiation expected in the first half of 2025 and topline results expected in the second half of 2026. We believe these trials will directly support our ultimate therapeutic goal of developing an all-oral combination product for obesity. We also intend to initiate an insulin sensitivity proof-of-concept trial of azelaprag monotherapy in the first half of 2025 to support potential indication expansion. We expect to report topline results from this proof-of-concept trial in the second half of 2025. We are also developing orally available small molecule brain-penetrant NLRP3 inhibitors for the treatment of diseases driven by neuroinflammation. We anticipate submitting an Investigational New Drug application (IND) for an NLRP3 inhibitor in the second half of 2025 and, if cleared, initiating a Phase 1 clinical trial in the first half of 2026. Our approach: Targeting human aging biology to treat chronic metabolic diseases The burden of many serious and chronic diseases—including cardiovascular disease and diabetes—increases with age. However, there is substantial natural variation in the human population, resulting in a broad range of aging trajectories and outcomes, with some people experiencing much longer lifespans as well as delayed disease onset. We created our company to identify biological pathways associated with longer, healthier human lifespans and to develop pharmaceutical products that can modulate these pathways with the intent to prevent and reverse specific diseases, focusing on metabolic diseases. --- Our approach starts with human data. We examine the impact of the molecular changes that happen naturally as people age and study how these changes drive both functional decline (e.g., loss of muscle strength) and disease risk (e.g., obesity, insulin resistance, dyslipidemia, hypertension). To develop new insights into the biological drivers of aging, we have generated proprietary longitudinal human datasets based on exclusive access to a unique resource: serial biobanked human samples coupled with health records and functional measurements collected for up to 50 years, capturing individual aging trajectories measured over several decades. We analyze these samples using state-of-the-artmolecular profiling technologies, measuring thousands of biologically relevant molecules, and then apply computational tools to the resulting data to extract potential drivers of a long and healthy lifespan. --- We have selected chronic metabolic diseases as our primary focus within age related chronic diseases, given their high prevalence and resulting potential for impact on population health. Chronic metabolic diseases represent some of the largest addressable therapeutics markets. Through our approach, we expect to target outsized commercial opportunities, initially within the obesity and diabetes landscape. For instance, according to third-party estimates, the global market for GLP-1R agonists, including those used to treat diabetes, is expected to grow to $150 billion by 2031. We were incorporated under the laws of the State of Delaware on April 1, 2015, under the name BioAge Labs, Inc. Our principal executive offices are located at 1445A South 50th Street, Richmond, California.

Cognition Therapeutics NASDAQ:CGTX

$0.72 +0.02 (+2.60%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$0.72 +0.01 (+0.72%)

As of 10/23/2026 07:30 PM Eastern

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

Eyepoint Pharmaceuticals NASDAQ:EYPT

$0.40 -0.02 (-5.51%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$0.41 +0.00 (+1.11%)

As of 10/23/2026 07:56 PM Eastern

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Vanda Pharmaceuticals NASDAQ:VNDA

$4.01 -0.04 (-0.99%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$3.99 -0.02 (-0.52%)

As of 10/23/2026 07:56 PM Eastern

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CGTX, BIOA, EYPT, and VNDA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CGTX, BIOA, EYPT, and VNDA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CGTX, BIOA, EYPT, and VNDA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGTX, BIOA, EYPT, and VNDA Company Descriptions

BioAge Labs NASDAQ:BIOA

Cognition Therapeutics NASDAQ:CGTX

Eyepoint Pharmaceuticals NASDAQ:EYPT

Vanda Pharmaceuticals NASDAQ:VNDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CGTX, BIOA, EYPT, and VNDA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CGTX, BIOA, EYPT, and VNDA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CGTX, BIOA, EYPT, and VNDA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGTX, BIOA, EYPT, and VNDA Company Descriptions

BioAge Labs NASDAQ:BIOA

Cognition Therapeutics NASDAQ:CGTX

Eyepoint Pharmaceuticals NASDAQ:EYPT

Vanda Pharmaceuticals NASDAQ:VNDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools